BRAF V600E Mutation
BRAF V600E mutation
Formalin-fixed paraffin embedded tissue (FFPE)
5-10 10µm sections of FFPE tissue in a sterile cup with stained H&E of same block.
If tumor percentage is less than 10% of total nuclei, macrodissection is required, send 5-10 10µm thickness unstained slides with stained H&E of same block.
Storage and stability information:
Once per week
Real-time Polymerase Chain Reaction (PCR)
No BRAF V600E mutation detected
BRAF is found in approximately 15% of colon tumors that do not contain a KRAS mutation. Patients whose colon cancer is positive for the BRAF mutation have poor response to anti-EGFR therapy and a worse prognosis based on time to progression and survival data, especially when the cancer is microsatellite stable.
Detection of the BRAF mutation is also useful in aiding the diagnosis of papillary thyroid carcinoma or anaplastic thyroid carcinoma, and in the identification of melanoma tumors that may respond to BRAF-targeted therapies